Finally, since the third-generation EGFR-TKI osimertinib replaced early-generation EGFR-TKIs for the frontline treatment of metastatic EGFR-mutated NSCLC, our results need to be validated in this clinical setting as well. This evidence concerns the gene EGFR and non-small cell lung carcinoma.